09 December 2024
Air Haifa to launch Athens flights
Air Haifa is currently operating all its flights from Ben Gurion airport but from December 22, Air Haifa will commence operating flights from its home base at Haifa airport.
Privacy protection regulator aims to make directors more proactive
At a conference organized by Pearl Cohen Zedek Latzer Baratz law firm Privacy Protection Authority legal advisor Adv. Reuven Eidelman warned that due to the rise in cyberattacks and data security events, directors are required to ensure the preparedness of their companies.
Snyk CEO favors Wall Street IPO in 2026
Peter McKay told “TechCrunch’: We’ve got $435 million in the bank and are very close to break-even. In 2025, we won’t burn any cash, so I can pick the time when I go public. I don’t need to rush.”
Israel's forex reserves back on the rise
Israel’s foreign exchange reserves at the end of November 2024 rose to $217.1 billion, an increase of $1.026 billion from their level at the end of October, the Bank of Israel reports.
Shekel starts week with more strong gains
Bank Leumi: With the hope that uncertainty will subside, the fundamental forces, such as the current account surplus, continue to support the appreciation of the shekel.
eToro aims at $5b IPO valuation
The company is buoyed by improved profits, and the expectation of more liberal regulation in US financial markets when Donald Trump becomes president.
03 December 2024
BoI governor: No immediate interest rate cut
Talking to "Globes" editor Naama Sikuler at the Israel Business Conference, Governor of the Bank of Israel Amir Yaron said cutting interest rates now would be like putting out a fire with gasoline. He also criticized the make-up of the 2025 budget.
Adam Neumann admits mistakes, reveals plans
In a rare public appearance, Neumann told the Globes Business Conference what he learned from WeWork's collapse, discussed his new venture Flow, and explained why he is investing in Israel.
02 December 2024
Trial success boosts NovoCure
The company's share price is up over 30% after it announced the results of the trial of its product in treating pancreatic cancer.